Monitor upcoming clinical catalysts: additional Phase 1 CITY-FXI data (late 2026), Phase 1 CITY-RBP4 initiation (late 2026), and CITY-TFR2 IIT start in China (late 2026). The IPO provides ~2-year cash runway, but the company will need additional capital for Phase 3 development and will likely seek a collaboration partner for CITY-FXI before Phase 3.
Executive Summary
City Therapeutics priced its IPO of 11,111,111 shares at $18.00 per share, raising approximately $200 million in gross proceeds ($186 million net before expenses). The clinical-stage RNAi biotech will use the funds to advance its lead pipeline (CITY-FXI, CITY-RBP4, CITY-TFR2) and City Platform, with cash runway into late 2028. The IPO creates a public market for CTY on Nasdaq, but the company remains pre-revenue with no approved products and significant accumulated losses.
Key Financial Metrics
Key Facts
- IPO of 11,111,111 shares at $18.00/share, gross proceeds of $199,999,998
- Underwriters have 30-day option for an additional 1,666,666 shares
- Net proceeds estimated at ~$181.5 million ($209.4 million if overallotment exercised)
- Pro forma as adjusted cash, cash equivalents, and restricted cash: $353.8 million
- Pro forma as adjusted total stockholders' equity: $338.9 million
- Common stock to be outstanding after IPO: 51,721,168 shares (53,387,834 if overallotment)
- Nasdaq listing under ticker CTY, expected delivery October 19, 2026
- Net losses of $58.5M (FY2025) and $53.4M (H1 2026); accumulated deficit of $142.5M as of June 30, 2026
- No revenue from product sales; collaboration revenue of $13.6M (FY2025) and $6.4M (H1 2026)
- Use of proceeds: $30M CITY-FXI, $20M CITY-RBP4, $40M CITY-TFR2, $70M City Platform, remainder for working capital
Financial Impact
IPO raises ~$200M gross; net proceeds ~$181.5M; pro forma cash position $353.8M; existing stockholders paid weighted-average $7.42/share vs. IPO price of $18.00/share, resulting in $11.19/share dilution to new investors
Risk Factors
- Pre-revenue clinical-stage biotech with no approved products and significant accumulated losses ($142.5M)
- Early-stage pipeline: CITY-FXI in Phase 1, CITY-RBP4 and CITY-TFR2 not yet in clinical trials
- Substantial additional capital required for later-stage development; may need to seek partnership for CITY-FXI before Phase 3
- Dilution to IPO investors: $11.19/share dilution (62% of IPO price)
- Reliance on third-party manufacturers and CROs; single-source supply chain risks
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001104659-26-116636 |
| Document: 0001104659-26-116636-index-headers.html | 0001104659-26-116636 |
| Document: 0001104659-26-116636-index.html | 0001104659-26-116636 |
| Document: 0001104659-26-116636.txt | 0001104659-26-116636 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13D | — | awaiting T+1 | — | — |
Oct 26, 2026 today | SC 13G | — | awaiting T+1 | — | — |
Oct 22, 2026 4d ago | SC 13G | $20.77 $20.77 | · 0.00% | ▲ +0.52% | $20.79 (+0.10%) |
Oct 19, 2026 7d ago | Insider Cluster | $20.83 $20.43 | ▼ −1.92% | ▼ −2.45% | $20.79 (−0.19%) |
Oct 19, 2026 7d ago | Press Release | $20.83 $20.43 | ▼ −1.92% | ▼ −2.45% | $20.79 (−0.19%) |
Oct 16, 2026 10d ago | 424B4 | $21.46 $20.83 | ▼ −2.94% | ▼ −3.27% | $20.79 (−3.12%) |
Oct 16, 2026 10d ago | EFFECT | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $20.79 (−7.19%) |
Oct 15, 2026 10d ago | 3 | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $20.79 (−7.19%) |
Oct 15, 2026 10d ago | 3 | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $20.79 (−7.19%) |
Oct 15, 2026 10d ago | 3 | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $20.79 (−7.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers